Tesamorelin and post-meal injections: how long after eating can you have an injection?

Tesamorelin is usually recommended to be taken on a relatively empty stomach, with many therapeutic protocols suggesting waiting around 1.5 to 2 hours after eating before administering a tesamorelin injection to support natural growth hormone signalling [1–4]. Although most clinical trials have mainly focused on dosage rather than exact meal timing, the topic of „Tesamorelin and fasting” is often discussed as fasting conditions are generally preferred – high insulin and blood sugar levels can temporarily reduce the body's natural growth hormone secretion.

Tesamorelin works by mimicking growth hormone-releasing hormone (GHRH), a natural hormone that signals the pituitary gland to release endogenous growth hormone (GH), which is GH naturally produced by the body [1,2]. As GH levels increase, so does insulin-like growth factor-1 (IGF-1) [1,2]. In normal physiology, growth hormone secretion tends to increase during fasting and decrease after meals, particularly those high in carbohydrates or sugar. For this reason, many clinicians recommend taking tesamorelin when insulin levels are lower, such as at bedtime or several hours after the last meal of the day.

Clinical trials evaluating tesamorelin in the context of HIV-related lipodystrophy and fatty liver disease have consistently used a once-daily dosing regimen, yet have generally not required strict meal timing guidelines [3–6]. Nevertheless, because glucose and insulin can suppress GH secretion, clinical practice often advises fasting prior to tesamorelin administration to potentially enhance the hormonal response.

Many therapeutic protocols also recommend avoiding food for approximately 30 to 60 minutes after tesamorelin injection. The purpose of this recommendation is to allow for the tesamorelin-stimulated GH release to occur before insulin levels rise again after a meal. Although direct studies comparing meal timing are limited, administration in a fasted state remains a common approach when using GHRH analogues such as tesamorelin.

Tesamorelin generally demonstrated stable blood sugar control in clinical trials, despite increasing the activity of the GH–IGF-1 pathway. In the studies by Falutz J et al. (2007, 2010), tesamorelin significantly reduced visceral fat without causing a significant worsening of fasting glucose or HbA1c levels in most participants [3,4]. HbA1c is a long-term marker used to assess average blood sugar levels over a period of months. Similarly, Stanley TL et al. (2019) observed no significant differences in fasting glucose or HbA1c levels compared to placebo during long-term tesamorelin treatment [5].

Generally speaking, though specific fasting recommendations can vary, tesamorelin is often administered around 1.5 to 2 hours after eating, and many individuals wait at least 30 minutes post-injection before consuming a meal again to support more natural growth hormone secretion patterns [1-5].

Where to inject Tesamorelin and how to administer it correctly?

Tesamorelin is administered as a subcutaneous injection, most commonly into the abdominal area, and injection sites are usually rotated regularly to help minimise irritation and local skin reactions [1–4]. A subcutaneous injection means the drug is delivered into the fatty tissue located just beneath the skin, rather than directly into a muscle. Clinical trials have consistently used daily subcutaneous injections into the abdomen as the standard method for administering tesamorelin.

Tesamorelin is usually supplied as a lyophilised powder, meaning it has been freeze-dried for increased stability and requires reconstitution with sterile or bacteriostatic water before use [1,2]. Once the solution is prepared, the prescribed dose is drawn into an insulin syringe and injected subcutaneously.

The abdomen is the preferred injection site in most studies and therapeutic protocols. It is usually recommended to inject in the abdominal area, avoiding the area directly around the navel, scar tissue, bruised skin, irritated skin, or active reaction sites [1–3]. Daily rotation of injection sites can help reduce the risk of redness, swelling, discomfort, bruising, or itching, which are among the most frequently reported injection site reactions in clinical trials.

The typical serving process usually involves the following steps:

• Dissolve tesamorelin powder using the provided diluent or bacteriostatic water according to the product instructions.
• Gently swirl the vial until the solution becomes clear. Vigorous shaking is usually avoided as peptides can be sensitive to excessive agitation.
• Draw up the prescribed dose into a syringe.
• Clean the selected injection site on the abdomen with an alcohol swab.
• Pinch a fold of skin and insert the needle subcutaneously at approximately a 90-degree angle.
• Inject the medicine slowly and evenly.
• Remove the needle and safely dispose of the syringe in the appropriate medical waste bin.

Clinical studies by Falutz J et al. (2010) and Stanley TL et al. (2014) used daily subcutaneous injections of 2 mg tesamorelin to reduce visceral abdominal fat and liver fat in HIV-positive individuals [3,4]. Similar injection methods were also used in long-term metabolic and NAFLD studies [5,6].

Reactions at the injection site are among the most commonly reported adverse events of tesamorelin. In clinical studies, some participants experienced mild redness, itching, swelling, bruising, or discomfort at the administration site, although serious injection-related complications were rare [3–6].

In general, tesamorelin is administered by daily subcutaneous injection into the abdominal area, using proper sterile technique and regular rotation of injection sites to improve comfort and limit local irritation.

Disclaimer

The content is for educational and scientific information purposes only and should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. Tesamorelin is a prescription medication that requires medical supervision. Meal timings, fasting practices, and dosing schedules should be individually determined by a qualified healthcare professional. Tesamorelin should only be prepared and administered under the supervision of a qualified healthcare professional. Incorrect injection technique or unsupervised peptide use may increase the risk of adverse events or complications.

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available at: NCBI Bookshelf: Tesamorelin – An Overview
2. PubChem. (2025). Tesamorelin Compound Summary. National Centre for Biotechnology Information. Available at: PubChem: Tesamorelin Summary
3. Falutz J, Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicentre, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
4. Stanley TL, Feldpausch, M. N., Oh, J., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomised clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
5. Stanley TL, Fourman, L. T., Feldpausch, M. N., et al. (2019). Effect of tesamorelin on non-alcoholic fatty liver disease in HIV-positive individuals: A randomised, double-blind, multicentre study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
6. Falutz J, Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058